FLT3 and acute myeloid leukemia: Since 2017, targeted therapies, including venetoclax, FLT3 inhibitors, and IDH inhibitors, have been approved for older adults with AML (age 60 years and older) [10], and there is the assumption that these treatments can also be applied to children with AML.